EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieÄquivalenzstudie

Efficacy and Safety of Yinhua Miyanling Tablets for Uncomplicated Urinary Tract Infections: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Non-inferiority Clinical Trial

Zhen Du, Yi-Wen Tang, Lu-Dong Qiao, Liang Cui, Hui-Ling Wu, Jin-Qiang Yang, Feng Liu, Zhuo Yin, Jian Zhang, Tie-Jun Pan, Shan Chen, Zhan Gao

Chinese Journal of Integrative Medicine · 2026-07 · 32 (7) · 588-595

DOI: 10.1007/s11655-026-4154-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Chinese Journal of Integrative Medicine, online erschienen am 16.04.2026. Verfasst von Zhen Du und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China. Hauptthemen laut MEDLINE: Urinary Tract Infections, Drugs, Chinese Herbal. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To compare the efficacy and safety of Yinhua Miyanling Tablets (YMT) versus levofloxacin in the treatment of female patients with uncomplicated urinary tract infections (uUTIs). METHODS: A multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical trial was conducted from August 2022 to August 2023 in 9 tertiary hospitals across China. By using a block randomization method, 480 female patients with uUTI were randomized in a 1:1 ratio to receive either YMT 2 g, 4 times daily for 7 consecutive days (plus levofloxacin-matching placebo) or levofloxacin tablets 0.5 g, once daily for 3 consecutive days (plus YMT-matching placebo). The primary outcome was the proportion of patients requiring additional antimicrobial therapy for uUTIs between day 1 and days 38-42 of treatment, while the secondary outcomes included the Acute Cystitis Symptom Score (ACSS) and urinalysis after 42-d treatment. Safety assessments were conducted based on all adverse events (AEs) and abnormal laboratory test results. RESULTS: A total of 458 women with uUTIs were enrolled in the modified intention-to-treat analysis. Between day 1 and days 38-42 of treatment, the proportion of patients requiring additional antimicrobial therapy was 20.8% (47/226) in the YMT group and 9.9% (23/232) in the levofloxacin group (P 0.05). The incidence of treatment-emergent AEs was 7.7% (17/226) in the YMT group and 7.0% (16/232) in the levofloxacin group (P=0.775). CONCLUSIONS: YMT is non-inferior to levofloxacin in the proportion of patients requiring additional antimicrobial therapy during treatment of uUTIs in women. YMT treatment is as effective as levofloxacin in terms of improving uUTI symptoms and quality-of-life scores. YMT may be used as a promising adjunctive therapy for uUTIs in women. (Trial registration No. ChiCTR2200066312).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsDrugs, Chinese HerbalHumansFemaleDouble-Blind MethodTabletsAdultMiddle AgedTreatment OutcomeLevofloxacin

Stichwörter der Autor:innen

Chinese medicineYinhua Miyanling Tabletsantibiotic uselevofloxacinnon-inferiority clinical trialrandomized controlled trialuncomplicated urinary tract infection

Substanzen

TabletsDrugs, Chinese HerbalLevofloxacin

Autor:innen und Institutionen

  • Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
  • Graduate School of Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Department of Urology, Civil Aviation General Hospital, Beijing, 100123, China.
  • Department of Urology, Jinhua People's Hospital, Jinhua, Zhejiang Province, 321001, China.
  • Department of Urology, Beijing Shunyi District Hospital, Beijing, 101300, China.
  • Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.

Zitieren

APA

Du, Z., Tang, Y. W., Qiao, L. D., Cui, L., Wu, H. L., Yang, J. Q., Liu, F., Yin, Z., Zhang, J., Pan, T. J., Chen, S., & Gao, Z. (2026). Efficacy and Safety of Yinhua Miyanling Tablets for Uncomplicated Urinary Tract Infections: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Non-inferiority Clinical Trial. Chinese Journal of Integrative Medicine, 32(7), 588-595. https://doi.org/10.1007/s11655-026-4154-4

Vancouver

Du Z, Tang YW, Qiao LD, Cui L, Wu HL, Yang JQ, et al. Efficacy and Safety of Yinhua Miyanling Tablets for Uncomplicated Urinary Tract Infections: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Non-inferiority Clinical Trial. Chinese Journal of Integrative Medicine. 2026;32(7):588-595. doi:10.1007/s11655-026-4154-4

BibTeX
@article{Du2026,
  author = {Du, Zhen and Tang, Yi-Wen and Qiao, Lu-Dong and Cui, Liang and Wu, Hui-Ling and Yang, Jin-Qiang and Liu, Feng and Yin, Zhuo and Zhang, Jian and Pan, Tie-Jun and Chen, Shan and Gao, Zhan},
  title = {Efficacy and Safety of Yinhua Miyanling Tablets for Uncomplicated Urinary Tract Infections: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Non-inferiority Clinical Trial},
  journal = {Chinese Journal of Integrative Medicine},
  year = {2026},
  volume = {32},
  number = {7},
  pages = {588--595},
  doi = {10.1007/s11655-026-4154-4}
}
Kostenlos starten →